BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 8682282)

  • 21. Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients.
    Gago FE; Tello OM; Diblasi AM; Ciocca DR
    J Steroid Biochem Mol Biol; 1998 Dec; 67(5-6):431-7. PubMed ID: 10030692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.
    Horita K; Yamaguchi A; Hirose K; Ishida M; Noriki S; Imamura Y; Fukuda M
    Eur J Histochem; 2001; 45(1):73-84. PubMed ID: 11411868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks.
    Le Goff JM; Lavayssière L; Rouëssé J; Spyratos F
    Anticancer Res; 2000; 20(3B):2213-8. PubMed ID: 10928180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.
    Harbeck N; Thomssen C; Berger U; Ulm K; Kates RE; Höfler H; Jänicke F; Graeff H; Schmitt M
    Breast Cancer Res Treat; 1999 Mar; 54(2):147-57. PubMed ID: 10424405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
    Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C
    Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical parameters for prognostic evaluation in patients with breast cancer.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Sampognaro E; Meo S
    Anticancer Res; 1994; 14(2B):693-8. PubMed ID: 8010728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunohistochemical detection of epidermal growth factor receptor (EGF-R) in paraffin sections of breast carcinoma tissue: correlation and clinical significance].
    Beckmann MW; Tutschek B; Göhring UJ; Engels K; Picard FK; Scharl A; Niederacher D; Schnürch HG
    Geburtshilfe Frauenheilkd; 1995 May; 55(5):258-65. PubMed ID: 7607382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical detection of epidermal growth factor receptor lacks prognostic significance for breast carcinoma.
    Göhring UJ; Ahr A; Scharl A; Weisner V; Neuhaus W; Crombach G; Holt JA
    J Soc Gynecol Investig; 1995; 2(4):653-9. PubMed ID: 9420872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
    Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
    J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis.
    Gasparini G; Toi M; Biganzoli E; Dittadi R; Fanelli M; Morabito A; Boracchi P; Gion M
    Oncology; 2001; 60(1):72-80. PubMed ID: 11150912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
    J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
    Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.
    Gasparini G; Weidner N; Bevilacqua P; Maluta S; Dalla Palma P; Caffo O; Barbareschi M; Boracchi P; Marubini E; Pozza F
    J Clin Oncol; 1994 Mar; 12(3):454-66. PubMed ID: 7509851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation].
    Ruibal A; Arias JI; Resino C; Lapeña G; Schneider J; Tejerina A
    Rev Esp Med Nucl; 2001 Aug; 20(5):365-8. PubMed ID: 11470070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
    Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
    Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cathepsin D expression by cancer and stromal cells in breast cancer: an immunohistochemical study of 1348 cases.
    Têtu B; Brisson J; Lapointe H; Wang CS; Bernard P; Blanchette C
    Breast Cancer Res Treat; 1999 May; 55(2):137-47. PubMed ID: 10481941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age-associated biomarker profiles of human breast cancer.
    Eppenberger-Castori S; Moore DH; Thor AD; Edgerton SM; Kueng W; Eppenberger U; Benz CC
    Int J Biochem Cell Biol; 2002 Nov; 34(11):1318-30. PubMed ID: 12200028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.